Dr Danuta Jeziorska outlines that the UK has a unique opportunity to lead in genomics and AI-driven precision medicine, but a critical early-stage funding gap—particularly for drug target discovery companies—threatens its global competitiveness.
PACE has launched its second funding round, with up to £5 million available to support cutting-edge diagnostic projects. This funding is part of a broader £30 million investment to address the global challenge of AMR.
